Harvest Fund Management Co. Ltd Purchases 1,399 Shares of DaVita Inc. (NYSE:DVA)

Harvest Fund Management Co. Ltd increased its holdings in DaVita Inc. (NYSE:DVA) by 14.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,142 shares of the company’s stock after purchasing an additional 1,399 shares during the period. Harvest Fund Management Co. Ltd’s holdings in DaVita were worth $1,826,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Harvard Management Co. Inc. purchased a new stake in DaVita during the 2nd quarter valued at $55,115,000. Point72 Asset Management L.P. bought a new stake in shares of DaVita during the 2nd quarter worth approximately $9,615,000. KBC Group NV boosted its holdings in DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after acquiring an additional 67,250 shares during the period. International Assets Investment Management LLC bought a new position in DaVita in the 3rd quarter valued at $10,346,000. Finally, Hennessy Advisors Inc. purchased a new stake in DaVita in the second quarter worth $8,439,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DaVita stock opened at $166.99 on Tuesday. The company has a 50 day moving average price of $158.34 and a 200 day moving average price of $148.65. The firm has a market capitalization of $13.69 billion, a P/E ratio of 18.01, a PEG ratio of 0.93 and a beta of 0.89. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 52 week low of $98.26 and a 52 week high of $169.12.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.85 EPS. Sell-side analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DVA. Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Truist Financial increased their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, UBS Group increased their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.